I am honored to be named the editor-in-chief of the journal Breast Cancer in November 2022. Breast Cancer, launched in 1994, is the official journal of the Japanese Breast Cancer Society, which contributes to progress in the breast cancer research including basic, translational and clinical research, and develops a new focus and new perspectives for all who are concerned with breast cancer.

Breast Cancer welcomes original articles, review articles, rapid communications, and high-quality case reports regarding breast cancer and relevant disease.

Our mission is to promote basic, translational, and clinical research on breast cancer to provide new scientific view in the field. Since Breast Cancer first received Impact Factor of 1.888 in 2010, it has been 12 years and it is now 3.307 in 2022. We need to continue all the efforts to understand the biology and clinical behavior of breast cancer by stimulating scientific discussions in the world and publishing relevant high-quality research articles. In addition, we need to stimulate discussions with society regarding what is needed and what is lacking in this filed to improve oncological environment to achieve our goal, making cancer benign.

We are open to world and society and welcome all types of research regarding breast oncology including scientific research, clinical studies, socioeconomic studies, and new technologies such as artificial intelligence and metaverse. In particular, we respect diverse viewpoints from different fields, which can be taken into and merged with breast oncology to evolve breast cancer research.

We sincerely thank the former editors-in-chief who have contributed to the development and advancement of the journal Breast Cancer: Drs. Yasuo Nomura, Masakuni Noguchi, Masahiro Hiraoka, Shinzaburo Noguchi, Masakazu Toi, and Yasuo Miyoshi. We will keep our eyes open and make every effort to promote breast cancer research to make cancer benign.